Cynapsus Therapeutics Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 1,535 818 891 457
Sales, General and Admin. 2,926 1,629 1,249 1,146
Non-Recurring Items - - - -
Other 57 61 14 15
Operating Income (4,518) (2,509) (2,154) (1,618)
Income From Continuing Operations
Add'l Income/Expense Items 524 540 (14) 243
Earnings Before Interest and Tax (5,080) (1,969) (2,168) (1,608)
Interest Expense 178 1,108 628 77
Earnings Before Tax (5,258) (3,077) (2,796) (1,684)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (4,173) (3,077) (2,796) (1,452)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (4,173) (3,077) (2,796) (1,452)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (4,173) (3,077) (2,796) (1,452)